PSYBF (PsyBio Therapeutics) Short-Term Debt: $0.00 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PsyBio Therapeutics Short-Term Debt?

PsyBio Therapeutics PSYBF -90.00% Short-Term Debt is $0.00 Mil as of Jun. 2023.

PsyBio Therapeutics's Short-Term Debt for the quarter that ended in Jun. 2023 was $0.00 Mil.

PsyBio Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

PsyBio Therapeutics Short-Term Debt Related Terms

PsyBio Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for PsyBio Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PsyBio Therapeutics Short-Term Debt Chart

PsyBio Therapeutics Annual Data
Trend Dec21 Dec22
Short-Term Debt
0.00 0.00

PsyBio Therapeutics Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
PsyBio Therapeutics (PSYBF) has a Short-Term Debt of $0.00 Mil as of Jun. 2023.
Is PsyBio Therapeutics' Short-Term Debt too high?
PsyBio Therapeutics' current Short-Term Debt is $0.00 Mil.
How does PsyBio Therapeutics' Short-Term Debt compare to VRTX and REGN?
PsyBio Therapeutics' Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. PsyBio Therapeutics's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PsyBio Therapeutics stock overvalued right now?
PsyBio Therapeutics (PSYBF) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For PsyBio Therapeutics (PSYBF), the current Short-Term Debt is $0.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PsyBio Therapeutics Business Description

Address 1624 Washington Street, Denver, CO, USA, 80203
PsyBio Therapeutics Corp is a biotechnology company. The company is engaged in the development of drugs intended for the treatment of mental illness and neurological disorders.